3 years 0.22
Extreme 0.2157
3.4
5 years 0.22
Extreme 0.2157
112.87
10 years 0.22
Extreme 0.2157
157.98
Manager TitleAgeSince
Chief Executive Officer 59 2025-05-14
Date Insider Type Main position Quantity % Market Cap. Importance
5/15/25 Issuer sale

Director

332,932 0.3726%
5/15/25 Issuer sale

Director

195,786 0.2191%
5/15/25
BVF Partners LP
Issuer saleCompany 16,312,872 18.2586%
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%-.--% - - 29.74M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
-0.33%+4.59%+26.94%+51.95% 45.81B
-1.07%+2.32%+21.80%+123.80% 43.46B
+0.21%+5.67%+251.90%+924.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average +0.28%+0.54%+49.32%+157.92% 42.43B
Weighted average by Cap. +0.41%+0.78%+47.70%+159.65%
Logo Allakos Inc.
Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.
Employees
61
  1. Stock Market
  2. Stocks
  3. ALLK Stock